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MaNovel targeted cancer therapies, especially kinase inhibitors, have revolutionized the treatment of many cancers and have
dramatically improved the survival of several types of malignancies. Because kinases not only are important in cancer
development and progression, but also play a critical role in the cardiovascular (CV) system and metabolic homeostasis,
important CV and metabolic sequelae have been associated with several types of kinase inhibitors. This paper reviews the
incidences and highlights potential mechanisms of vascular and metabolic perturbations associated with 3 classes of
commonly used kinase inhibitors that target the vascular endothelial growth factor signaling pathway, the ABL kinase,
and the phosphoinositide 3-kinase/AKT/mammalian target of rapamycin signaling pathway. We propose preventive,
screening, monitoring, and management strategies for CV care of patients treated with these novel agents.
(J Am Coll Cardiol 2015;66:1160–78) © 2015 by the American College of Cardiology Foundation.T he past decade has been marked by a revolu-tion in cancer therapy with the developmentof novel targeted therapies that have
improved the prognosis of many cancer types. This
progress has resulted, in part, from a new paradigm
for cancer treatment with an evolution from rela-
tively nonspeciﬁc cytotoxic agents to more selec-
tive, mechanism-based therapeutics. Unfortunately,
adverse short- and long-term cardiovascular (CV) tox-
icities are important considerations with some of the
novel therapies, prompting development of the new
clinical ﬁeld of cardio-oncology (also referred to as
“onco-cardiology”). Although there has been much
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of the novel cancer therapies have emerged as an
important issue.
Tyrosine and serine/threonine kinases are impor-
tant targets for cancer therapy, and these kinase in-
hibitors have become the fastest growing class of
anticancer drugs (1). In general, kinase inhibitors are
less toxic than older cancer therapies such as
anthracyclines, alkylating agents, or ionizing radia-
tion because they target cellular pathways that have
been hijacked by the cancer cell. However, as kinases
also play critical roles in the CV system, kinase inhi-
bition can have adverse CV effects (2). Toxicities
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AB BR E V I A T I O N S
AND ACRONYM S
BP = blood pressure
CTCAE = Common
Terminology Criteria for
Adverse Events
CV = cardiovascular
mTOR = mammalian target of
rapamycin
PI3K = phosphoinositide
3-kinase
RTK = receptor tyrosine kinase
TKI = tyrosine kinase inhibitor
VEGF = vascular endothelial
growth factor
VSP = vascular endothelial
growth factor signaling
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1161also plays a critical role in CV system. In this case,
such on-target toxicities may even serve as surrogates
for antitumor response (3). On the other hand, most
kinase inhibitors also inhibit kinases other than the
cancer-promoting target, resulting in off-target
toxicities.
Because many of the new kinase inhibitors target
the vasculature or cancer metabolism, vascular and
metabolic derangements have emerged as important
issues in cardio-oncology. Moreover, multiple tyro-
sine kinase inhibitors (TKIs) are known to cause thy-
roid dysfunction, which can potentially complicate
metabolic derangements (4). Coupled with the het-
erogeneity of both on- and off-target effects of spe-
ciﬁc agents, a wide spectrum of CV toxicities have
been associated with these kinase inhibitors. This
review will focus on the vascular and metabolic
toxicities associated with 3 categories of kinase in-
hibitors commonly used in cancer therapy, catego-
rized on the basis of their cellular targets: 1) kinase
inhibitors targeting the vascular endothelial growth
factor signaling pathway (VSP); 2) kinase inhibitors
targeting ABL kinase; and 3) kinase inhibitors targeting
the phosphoinositide 3-kinases (PI3Ks)/AKT/mamma-
lian target of rapamycin (mTOR) signaling pathway.
KINASES AS TARGETS FOR CANCER THERAPY
Kinases are enzymes that transfer $1 phosphate
group from adenosine triphosphate (ATP) to speciﬁc
protein or lipid substrates. Kinase-directed modiﬁ-
cations of these substrates control cell signaling,
which regulates diverse cellular functions. Dysregu-
lation of kinases can lead to a variety of pathologies,
including malignancy. Indeed, most human cancers
are associated with overactivation of kinases due to
somatic point mutations, chromosomal rearrange-
ments, or gene ampliﬁcations. There are approxi-
mately 20 lipid kinases and 518 protein kinases
encoded by the human genome. On the basis of their
substrate speciﬁcity, protein kinases can be further
categorized into tyrosine kinases (TKs), serine/
threonine kinases, and dual-speciﬁcity kinases. TKs
are the most important targets for cancer drug
development. For this reason, the majority of kinase
inhibitors currently approved or in clinical trials are
TKIs (5).
TKs can be classiﬁed as receptor tyrosine kinases
(RTKs) and nonreceptor TKs. RTKs span the plasma
membrane and are activated by binding of a ligand
(most commonly a growth factor) to the extracellular
domain, leading to dimerization of the receptor
and activation of signaling. In contrast, nonreceptor
TKs are located in the cytosol, the nucleus, or theinner surface of the plasma membrane and
play an important role in relaying intra-
cellular signals triggered by RTKs and other
cell-surface receptors (Central Illustration)
(6). To activate a substrate, kinases bind
both the substrate and ATP, then transfer a
phosphate group from ATP to the substrate,
leading to substrate phosphorylation and
activation.
Strategies to target kinases in cancer ther-
apy include (Central Illustration):
1. Small molecule kinase inhibitors (TKIs):
small molecules (molecular weight <1,000
Daltons) that interfere with binding of the
kinase to ATP or substrates. Most current
drugs targeting kinases belong to this
category.2. Monoclonal antibodies (mAbs) that bind the RTK or
its ligand. As a result, they can be further sub-
categorized into mAbs directed against RTKs to
prevent ligand binding (e.g., trastuzumab) or RTK
dimerization and activation (e.g., pertuzumab);
and mAbs directed against the circulating ligand to
prevent it from binding to its receptor (e.g.,
bevacizumab).
3. Soluble decoy receptors (“ligand traps”) bind the
ligand, preventing it from binding to its receptor.
Small molecule inhibitors have been especially
attractive for clinical use because they can be taken
orally and can target more than 1 kinase, thus proving
effective in several types of cancer.
CV ENDPOINTS IN ONCOLOGY TRIALS
VERSUS CV TRIALS
As life expectancy increases, many diseases that
predominantly affect older individuals will become
more prevalent. Advancing age is a risk factor for CV
disease, metabolic disorder, and cancer. Importantly,
cancer and CV disease also share other common risk
factors, such as tobacco use, obesity, and physical
inactivity (7). As a result, cancer patients frequently
have CV and metabolic comorbidities. Therefore, in
the assessment of new cancer therapies, it becomes
essential to distinguish between treatment-induced
CV and metabolic adverse effects from treatment-
independent events. A robust and consistent moni-
toring system with standard deﬁnitions for
treatment-associated CV and metabolic adverse
events is essential during the treatment course. In
addition, to deﬁnitively determine whether a therapy
causes CV disease, appropriate control groups are
prerequisites.
pathw
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Tyrosine kinases are divided into 2 main categories: receptor tyrosine kinases (RTKs) and non-RTKs. RTKs are activated upon binding of their respective ligands to their
extracellular domain, leading to activation of various signaling pathways and promoting survival of tumor cells. Strategies to inhibit tyrosine kinases include: monoclonal
antibodies (mAbs) targeting the ligand; soluble decoy receptors neutralizing the ligand; mAbs targeting the extracellular domain of RTKs and preventing RTK
dimerization and activation; and small molecular tyrosine kinase inhibitors (TKIs) blocking intracellular signaling pathways. ERK ¼ extracellular-signal-regulated kinase;
MEK ¼ mitogen-activated protein kinase kinase; mTOR ¼ mammalian target of rapamycin; PI3K ¼ phosphoinositide-3 kinase.
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1162Attempts to standardize CV endpoint deﬁnitions
between CV trials of CV drugs and devices (e.g.,
criteria advanced by the various Academic Research
Consortiums) and non-CV agents have been promul-
gated (e.g., Standardized Data Collection for Cardio-
vascular Trials Initiative), but have not been applied
prospectively to date to the vast majority of novel
anticancer agents. Instead, oncology clinical trials
typically use a version of the Common Terminology
Criteria for Adverse Events (CTCAE), a classiﬁcation
system developed by the National Cancer Institute toassess cancer therapy–related adverse events. The
CTCAE categorizes events by severity using a 1 to 5
scale, with grade 5 being assigned to death and grade
1 to 2 typically indicating mild adverse events (8). In
contrast, CV trials typically have focused the primary
endpoint on major adverse CV events. There are
major differences in reporting and grading of CV and
metabolic adverse events in oncology trials compared
with CV clinical trials, and these may limit detection
of CV toxicities and reduce the ability to compare
safety data among different cancer drugs (9) and
TABLE 1 CV Endpoints in Clinical Trials
CV Endpoint Endpoint Deﬁnition Reference Notes/Speciﬁc Endpoint Components
CV death Standardized Data Collection for Cardiovascular
Trials Initiative (10)
Includes death from AMI, sudden cardiac death, heart failure,
stroke, CV procedures, CV hemorrhage
Myocardial infarction Third Universal Deﬁnition of MI (101) Caution in determining MI in setting of severe underlying illness
such as end-stage cancer or infection, which may be associated
with biomarker elevation (102)
Unstable angina Standardized Data Collection for Cardiovascular
Trials Initiative (10)
Hospitalization recommended as a requirement
TIA/stroke Standardized Data Collection for Cardiovascular
Trials Initiative (10)
Imaging studies, severity determination (modiﬁed Rankin scale);
neurology participation in adjudication recommended;
ischemic versus hemorrhagic
Revascularization
PCI
CABG
Standardized Data Collection for Cardiovascular
Trials Initiative (10)
CABG and PCI; should be ischemia driven
Stent thrombosis Academic Research Consortium (103) Deﬁnite and probable stent thrombosis only
Peripheral arterial disease TRA 2P-TIMI 50 (104) Acute limb ischemia and peripheral revascularization
AMI ¼ acute myocardial infarction; CABG ¼ coronary artery bypass grafting; CV ¼ cardiovascular; MI ¼ myocardial infarction; PCI ¼ percutaneous coronary intervention; TIA ¼
transient ischemic attack; TRA 2P-TIMI 50 ¼ Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events–Thrombolysis In Myocardial
Infarction 50.
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1163assess them in relation to a similar noncancer popu-
lation. The need to standardize endpoints for CV
endpoint trials of both CV and non-CV medications
has also been recognized and codiﬁed by the Stan-
dardized Data Collection for Cardiovascular Trials
Initiative (10). Experience with diabetes medications,
which are mandated by the Food and Drug Adminis-
tration (FDA) to be studied for CV safety, has
demonstrated that large-scale trials can be conducted
with standard deﬁnitions (11). In addition, large,
multicenter CV trials invariably use central endpoint
adjudication committees to ensure standardization of
the endpoint process. One would hope that a similar
approach would be adopted in cancer trials in the
future, allowing for greater certainty in the CV
assessment process. Table 1 is a compilation of the
main CV endpoints that should be included in such an
approach and the basis for speciﬁc endpoint
deﬁnitions.
All considerations of CV endpoints in oncology
trials should be put in the context of speciﬁc cancer
type, cancer prognosis, and the duration of therapy.
For example, treatment of chronic myelogenous leu-
kemia (CML) has been transformed by targeted kinase
therapies, and patients may now have a near-normal
life expectancy. In contrast, the cancer prognosis
and duration of therapy are different for other cancer
types, particularly solid tumors such as kidney and
lung cancer. In this regard, communication between
the cardiologist and oncologist is critical for individ-
ual optimization of patient care.
Much of the current data regarding toxicities derive
from cancer clinical trials that excluded patients with
a history of CV disease or history of vascular and
metabolic disorders. Indeed, CV toxicities have thepotential to be more frequent in a “real-world” pop-
ulation, where many patients may have marginally or
even poorly controlled CV risk factors and underlying
vascular disease. Post-approval FDA databases may
help assess the CV safety of new cancer therapies in
the general population.
HYPERTENSION MONITORING AND
GRADING IN ONCOLOGY TRIALS
Older versions of CTCAE classiﬁcations for hyper-
tension (HTN) had little similarity to standard cardiac
deﬁnitions of HTN, such as those in the Joint National
Committee 7/8 guidelines (Table 2). More recent ver-
sions of CTCAE classiﬁcations for HTN are more
consistent with Joint National Committee 7/8 guide-
lines (12). Given this discrepancy, the incidence of
HTN in older oncology trials initiated prior to 2009
might be under-reported.
PERIPHERAL ARTERIAL DISEASE
AND OTHER VASCULAR TOXICITIES
Vascular events affecting the peripheral arteries are
an important vascular toxicity associated with certain
kinase inhibitors, but are generally not accurately
reported in the oncology trials because CTCAE uses
the vague term “peripheral ischemia” and captures
vascular events as “a disorder characterized by
impaired circulation to an extremity” (8). The major-
ity of cancer therapy case series and studies discussed
in this review used peripheral arterial occlusive dis-
ease interchangeably with peripheral arterial disease
to characterize vascular toxicity. The term “peripheral
arterial occlusive disease,” which is increasingly used
TABLE 2 Comparison of CTCAE V3.0, V4.0, and JNC 7/8
Grade 1 Grade 2 Grade 3 Grade 4 Grade 5
CTCAE version 3.0
(published in 2003)
Asymptomatic, transient (<24 h)
increase by >20 mm Hg
(diastolic) or to >150/100 mm Hg
if previously WNL; intervention
not indicated
Recurrent or persistent ($24 h)
or symptomatic increase by
>20 mm Hg (diastolic) or to
>150/100 mm Hg
if previously WNL; monotherapy
may be indicated
Requiring more than 1 drug
or more intensive therapy
than previously
Life-threatening
consequences
(e.g., hypertensive
crisis)
Death
CTCAE version 4.0
(published in 2009)
Pre-hypertension (SBP
120–139 mm Hg or
DBP 80–90 mm Hg)
Stage 1 HTN (SBP 140-159 mm Hg
or DBP 90-99 mm Hg);
medical intervention indicated;
recurrent or persistent ($24 h);
symptomatic increase by
>20 mm Hg (diastolic) or to
>140/90 mm Hg if previously
WNL; monotherapy
indicated
Stage 2 HTN (SBP $160 mm Hg
or DBP $100 mm Hg);
medical intervention indicated;
more than 1 drug or more
intensive therapy than
previously used indicated
Life-threatening
consequences
(e.g., malignant
hypertension,
transient or permanent
neurologic deﬁcit,
hypertensive crisis);
urgent intervention
indicated
Death
JNC 7/8 Normal BP: SBP <120 mm Hg; DBP <80 mm Hg
Pre-hypertension: SBP 120–139 mm Hg; DBP 80–90 mm Hg; treatment required in high-risk cardiovascular patients
Stage 1 HTN: SBP 140–159 mm Hg; DBP 90–99 mm Hg; treatment required
Stage 2 HTN: SBP $160 mm Hg; DBP $100 mm Hg; treatment required
BP ¼ blood pressure; CTCAE ¼ Common Terminology Criteria for Adverse Events; DBP ¼ diastolic blood pressure; HTN ¼ hypertension; JNC ¼ Joint National Committee; SBP ¼ systolic blood pressure;
WNL ¼ within normal limit.
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vascular events, does not fully reﬂect adverse events
that can occur in the cardiac and cerebral vasculature.
However, this term gives very little insight into the
speciﬁc pathophysiology (e.g., thrombosis vs.
atherosclerosis) (9). To understand the incidence
and severity of vascular toxicity in oncology studies, it
will be useful to develop deﬁnitions for vascular
events (VE) that match deﬁnitions commonly used in
CV clinical trials (10). In this review, we will use VE
to refer to both acute and chronic events related to
the peripheral circulation reported in the published
oncology data.
METABOLIC TOXICITIES
Hyperglycemia, hypertriglyceridemia, and hypercho-
lesterolemia are listed as metabolic adverse effects in
the current version of CTCAE (8). However, elevated
low density lipoprotein (LDL), which is more relevant
to adverse CV events, is not included.
VSP INHIBITORS
VASCULAR ENDOTHELIAL GROWTH FACTOR SIGNALING
IN TUMOR ANGIOGENESIS. Over a century ago, it was
hypothesized that tumors secrete factors that pro-
mote the formation of new blood vessels (angiogen-
esis), ensuring the delivery of nutrients and oxygen
for tumor growth (13). In 1971, Judah Folkman pro-
posed targeting angiogenesis to treat human cancer
(14). It took another 3 decades for the speciﬁc
signaling pathways that promote angiogenesis to beelucidated. Hypoxia and low-nutrient environments,
commonly found in the central region of solid tumors,
lead to the stabilization of hypoxia inducible factor-
1a, which in combination with its more stable partner,
hypoxia inducible factor-1b, bind to cellular hypoxia-
response elements that control angiogenesis. These
include vascular endothelial growth factor (VEGF),
platelet-derived growth factor (PDGF), and other gene
products that stimulate the development of new
vasculature, allowing the tumor to grow and metas-
tasize (15). In the past decade, agents that target tu-
mor angiogenesis, and speciﬁcally VSP, have become
effective cancer therapies.
The human VEGF family contains 5 glycoproteins:
VEGFA, VEGFB, VEGFC, VEGFD, and placental growth
factor (PIGF). All have a common VEGF homology
domain. They bind to 3 RTKs: VEGFR-1 (FLT-1),
VEGFR-2 (KDR/FLK-1), and VEGFR-3 (FLT-4), which
are found primarily on the surface of vascular and
lymphatic endothelial cells (ECs). Binding of the VEGF
ligand to VEGF receptors leads to receptor activation
and various cellular processes, including increased
proliferation, survival, permeability, and migration
(16). Although VEGFA binds to both VEGFR-1 and -2,
VEGFR-2 serves as themainmediator of themitogenic,
angiogenic and permeability-enhancing effects and
has, therefore, served as an important therapeutic
target (17) (Figure 1).
The VEGF signaling pathway can generally
be inhibited by 4 approaches: mAb directed against
circulating VEGF, soluble decoy receptor “VEGF trap,”
antibodies directed against VEGFR, or small-molecule
FIGURE 1 VEGF Signaling and Inhibition Strategies
The mammalian VEGF family consists of 5 glycoproteins (VEGFA, VEGFB, VEGFC, VEGFD, and PIGF) that bind and activate 3 structurally similar
receptor tyrosine kinases: VEGFR-1 (FLT-1), VEGFR-2 (KDR/FLK-1), and VEGFR-3 (FLT-4). VEGFA binds to both VEGFR-1 and -2; VEGFB and
PIGF bind exclusively to VEGFR-1. VEGFR-3 is a speciﬁc receptor for VEGFC and VEGFD. Binding of VEGF to the VEGFR causes dimerization and
autophosphorylation of the receptor, which activates downstream transduction pathways. VEGF-targeted approaches include: 1) mAbs tar-
geting VEGFA; 2) a VEGF trap binding VEGFA, VEGFB, and PIGF; 3) an mAb targeting VEGFR-2; 4) small-molecule TKIs with anti-VEGF activity;
and 5) speciﬁc VEGFR-2 inhibitors. FDA ¼ Food and Drug Administration; mAb ¼ monoclonal antibody; PIGF ¼ placental growth factor; RTK ¼
receptor tyrosine kinase; TKI ¼ tyrosine kinase inhibitor; VEGF ¼ vascular endothelial growth factor; VEGFR ¼ vascular endothelial growth
factor receptor; VSP ¼ vascular endothelial growth factor signaling pathway.
J A C C V O L . 6 6 , N O . 1 0 , 2 0 1 5 Li et al.
S E P T E M B E R 8 , 2 0 1 5 : 1 1 6 0 – 7 8 Cardiovascular and Cardiometabolic Effects of Kinase Inhibitors
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example, bevacizumab (Avastin, Genentech, South
San Francisco, California) is a fully humanized mAb
that binds and neutralizes circulating VEGFA. In
contrast, sunitinib and sorafenib are examples of
small-molecule TKIs that target the VEGF and other
receptors. Eight such small molecules (sunitinib, sor-
afenib, pazopanib, axitinib, vandetanib, regorafenib,
cabozantinib, and lenvatinib) have been approved by
the FDA so far, while multiple other inhibitors are
currently being tested in humans.
VSP INHIBITORS AND VASCULAR TOXICITIES. VSP
inhibitors are associated with various CV toxicities
including cardiomyopathy, HTN, arterial and/or
venous thrombosis, and renal vascular injury. VSP
inhibitor-associated cardiomyopathy was reviewed
previously (18); here, we focus on the vascular and
metabolic effects of these drugs.HYPERTENSION. Inc idence . HTN is the most com-
mon vascular toxicity associated with VSP inhi-
bitors. The incidences of HTN are summarized in
Table 3.
Nearly all patients treated with these agents
experience a rise in their blood pressure (BP). In 1
study, 54 normotensive patients treated with sor-
afenib underwent 24-h ambulatory BP monitoring;
93% had a rise in BP by day 6, and most experienced a
rise in BP in the ﬁrst 24 h of therapy (19). HTN may
also be dose-dependent and transient. In a study of
home BP monitoring in patients receiving sunitinib,
both systolic and diastolic BP had increased sub-
stantially by week 1 after initiation of sunitinib
and decreased within 1 to 2 weeks after stopping
therapy (20).
HTN as a biomarker for cancer response. Because HTN
represents an on-target sequelae of VSP inhibitors,
TABLE 3 Incidences and RRs of HTN Associated With VSP Inhibitors
Agent Molecular Targets Study (Ref. #)
Overall
Incidence
of HTN (%)
High-Grade HTN
(Grade 3 or 4) (%)
RR
All-Grade High-Grade
Bevacizumab
(mAb)
VEGFA Meta-analysis, 12,656 patients,
20 trials (105)
23.6 7.9 3.02 5.28
Pazopanib
(TKI)
VEGFR-1, VEGFR-3, PDGR-a, PDGFR-b,
and c-KIT
Meta-analysis, 1,651 patients,
13 trials (106)
35.9 6.5 4.97 2.87
Sunitinib
(TKI)
VEGFR-1, VEGFR-2, VEGFR-3, PDGR-a,
PDGFR-b, FLT-3, and CSF-1R
Meta-analysis, 4,999 patients,
13 trials (107)
21.6 6.8 3.44 22.72
Sorafenib
(TKI)
VEGFR-1, VEGFR-2, VEGFR-3, PDGR-a,
PDGFR-b, FLT-3, RAF-1, and BRAF
Meta-analysis, 4,722 patients,
55 trials (108)
23.1 6.0 3.06 3.20
Axitinib
(TKI)
VEGFR-1, VEGFR-2, VEGFR-3, PDGR-a,
PDGFR-b, and CSF-1R
Meta-analysis, 1,908 patients,
10 trials (109)
40.1 13.1 3.00 1.71
Vandetanib
(TKIs)
VEGFR-2, EGFR, and Ret Meta-analysis, 3,154 patients,
11 trials (110)
24.2 6.4 5.1 8.06
Regorafenib
(TKI)
VEGFR-1, VEGFR-2, VEGFR-3, TIE-2, PDGFR-b,
FGFR-1, RET, KIT, and RAF
Meta-analysis, 1,069 patients,
5 trials (111)
44.4 12.5 3.76 8.39
Cabozantinib
(TKI)
VEGFR-2, FLT-3, c-KIT, RET, and MET Phase III clinical trial,
214 patients (112)
32.7 8.4 NA NA
Aﬂibercept
(VEGF trap)
VEGF Meta-analysis, 4,451 patients,
15 trials (113)
42.4 17.4 4.47 4.97
Ramucirumab
(VEGFR2 inhibitor)
VEGFR-2 Meta-analysis, 3,851 patients,
11 trials (114)
20.0 8.6 2.77 3.58
Lucitanib
(TKI)
VEGFR-1, VEGFR-2, VEGFR-3, PDGR-a, PDGFR-b,
FGFR-1, and FGFR-2
1 phase I/IIa study,
76 patients (115)
91 58 NA NA
Lenvatinib
(TKI)
VEGFR-1, VEGFR-2, VEGFR-3, FGFRs
PDGFR-a, RET, and KIT
1 phase III trial,
261 patients (116)
69.3 42.9 NA NA
Apatinib
(TKI)
VEGFR-2 3 phase II trials (117–119) 39.1–64.4 8.51–36 NA NA
CSF-1R¼ colony stimulating factor-1 receptor; FGFR ¼ ﬁbroblast growth factor receptor; mAb ¼monoclonal antibody; NA ¼ not applicable; PDGFR¼ platelet-derived growth factor receptor; RR ¼ risk ratio;
TKI ¼ tyrosine kinase inhibitor; VEGF ¼ vascular endothelial growth factor; VEGFR ¼ vascular endothelial growth factor receptor; VSP ¼ vascular endothelial growth factor signaling pathway.
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meta-analysis, bevacizumab-induced HTN correlated
with tumor response in patients with metastatic
colorectal cancer (21). HTN also correlated with a
favorable outcome in other cancer types (22–24).
However, these studies were retrospective analyses.
In 1 small, prospective study of bevacizumab in 40
patients with recurrent glioblastoma, the develop-
ment of HTN did not predict better outcomes (25).
Large, prospective studies are needed to validate the
role of HTN as a marker for cancer response and
prognosis.
Relat ionsh ip between prote inur ia and HTN. Pro-
teinuria is frequently observed in patients treatedwith
VSP inhibitors and is often accompanied by HTN. In
a recent meta-analysis including 6,882 patients with
a variety of solid tumors treated with VSP inhibitors
from 33 trials, the incidence of all-grade and high-
grade proteinuria was 18.7% and 2.4%, respectively
(26). Proteinuria is usually aggravated by concomitant
HTN. In patients treated by bevacizumab, proteinuria
was present in 54% of patients with grade 2/3 HTN and
in only 16% of patients with grade 0/1 HTN (27). Pa-
tients with bevacizumab-induced proteinuria are alsomore commonly hypertensive (47.1% vs. 16.9%) (28).
VEGF inhibition is likely a causal mechanism for
both HTN and proteinuria, as demonstrated in other
conditions, such as pre-eclampsia (see the following
text).
Pathogenesis of VSP inhibitor-induced HTN. There have
been several proposed mechanisms for VSP-inhibitor
induced HTN. A combination of these diverse mech-
anisms is most likely to play a role in the pathogen-
esis of HTN.
Vasodilator and vasoconstrictor imbalance theory. VEGF
induces nitric oxide (NO)–dependent arterial relaxa-
tion (29) and up-regulates NO production in human
ECs via endothelial nitric oxide synthase phosphory-
lation and activation, thus playing an important
role in maintaining baseline vascular tone (30).
Conversely, bevacizumab decreases NO production
in vitro (31). VEGF also leads to the production
of another vasodilator, prostacyclin, and decreases
endothelin-1 levels, a potent vasoconstrictor. In-
creased circulating levels of endothelin-1 after suni-
tinib therapy have been reported in parallel to a rise in
BP in rodents, as well as in humans (32). Thus, the
imbalance between vasodilators and vasoconstrictors
FIGURE 2 Proposed Mechanisms of VSP Inhibitor–Induced Hypertension
(A) VEGF in the circulation binds to VEGFRs expressed on endothelial cells and activates multiple downstream signaling pathways, including
both Src and PI3K, resulting in activation of AKT kinase. AKT can directly phosphorylate and activate eNOS, leading to production of NO. VEGFR
activation also activates PLC, which triggers a signaling cascade resulting in transcriptional activation of COX-2, leading to the production of the
prostacyclin PGI2. Both NO and PGI2 are potent vasodilators. VEGFR activation also decreases production of ET-1 through unknown mecha-
nisms. VSP inhibitors can lead to decreased production of NO and PGI2, and increased production of ET-1, leading to HTN pathogenesis. (B)
VEGF maintains capillary network integrity. When the VSP is inhibited, rarefaction (reduction of the density of capillary beds) can occur, which
contributes to the development of HTN. (C) VEGF and the VEGFR are highly expressed in the kidneys, and VSP inhibitors can potentially alter
glomerular structure and function and decrease the glomerular ﬁltrate rate, leading to HTN pathogenesis. COX-2 ¼ cyclooxygenease-2; eNOS ¼
endothelial nitric oxide synthase; ET-1 ¼ endothelin-1; HTN ¼ hypertension; NO ¼ nitric oxide; PGI2 ¼ prostacyclin; PI3K ¼ phosphoinositide
3-kinase; PLC ¼ phospholipase C; other abbreviations as in Figure 1.
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opment of HTN (Figure 2A).
Peripheral vascular resistance theory. VEGF is an
important mediator for EC proliferation and survival.
Chronic VEGF inhibition causes reduced EC survival,
ultimately leading to a net reduction in tissue
microvessel density and capillary rarefaction (loss of
parallel capillary circulation) (33), which can increase
afterload and contribute to HTN pathogenesis
(Figure 2B).
Renal impairment theory. VEGF and VEGFR are highly
expressed in the kidneys and play important roles in
the proliferation, differentiation, and survival of
mesangial cells and ECs (34). VSP inhibitors may alterglomerular structure and function, leading to a
decreased glomerular ﬁltration rate and HTN
(Figure 2C).
“Pre-eclampsia–like” theory. Pre-eclampsia is charac-
terized by HTN, proteinuria, and edema, and it affects
up to 5% of pregnancies (35). Interestingly, this
similar paradigm of “pre-eclampsia–like” syndrome
has also been described in patients treated with VSP
inhibitors (36). Several lines of evidence strongly
implicate soluble fms-like tyrosine kinase receptor
(sFlt-1), secreted by the placenta, as playing a causal
role in the development of pre-eclampsia. sFlt-1,
also called soluble VEGFR-1, binds to VEGF and
PIGF, abrogating VEGF signaling, creating a condition
FIGURE 3 CV Risk Assessment and Monitoring During VSP Inhibitor Treatment
Continue VSP
Inhibitor Therapy
Controlled
Not
Controlled
Not
Controlled
1) Home BP monitoring is recommended
2) Check Urine ACR every 3 months
3) Avoid medications that are known to
    raise BP (such as erythropoietin,
    NSAIDs) if possible
BP<140 mm Hg and
DBP<90 mm Hg
Initiate VSP inhibitor
Controlled
BP<140 mm Hg and
DBP<90 mm Hg
Pretreatment Risk Assessment for Cardiovascular Complications
1) A thorough history: DM, cigarette smoking, pre-existing HTN, HLD, CVD, previously documented LVH
2) A thorough physical exam: repeated BP measurements
3) Lab and other tests: chemistry including BUN, Cr, urine ACR, lipid profile, baseline EKG
BP>140 mm Hg and/or
DBP>90 mm Hg
Treat HTN based on
current JNC7/8
guidelines
Hold or dose adjustment:
1) Uncontrolled HTN (SBP>160 mm Hg
    or DBP>100 mm Hg)
2) Uncontrolled HF
3) Unstable or poorly controlled angina
4) Significant proteinuria or kidney
     dysfunction
5) Uncontrolled arrhythmia
Cardiovascular (CV) risk factors should be carefully assessed before initiating VSP inhibitors. A thorough history and physical examination
should be performed for each patient. Baseline creatinine to assess kidney function, urine ACR to assess proteinuria, lipid proﬁle, and a baseline
electrocardiogram to assess LVH are recommended. Pre-existing HTN needs to be treated and controlled before starting VSP inhibitors. Given
the paucity of data, evidence-based recommendations cannot be made. ACEIs or ARBs are reasonable as ﬁrst-line therapy for VSP inhibitor–
induced HTN and proteinuria. ACEI ¼ angiotensin-converting enzyme inhibitor; ACR ¼ albumin creatinine ratio; ARB ¼ angiotensin II receptor
blocker; BP ¼ blood pressure; BUN ¼ blood urea nitrogen; Cr ¼ creatinine; CVD ¼ cardiovascular disease; DBP ¼ diastolic blood pressure;
DM ¼ diabetes mellitus; EKG ¼ electrocardiogram; HTN ¼ hypertension; JNC ¼ Joint National Committee; LVH ¼ left ventricular hypertrophy;
SBP ¼ systolic blood pressure; NSAID ¼ nonsteroidal anti-inﬂammatory drug; VSP ¼ vascular endothelial growth factor signaling pathway.
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1168similar to that induced by VSP inhibitors (37). Renal
biopsies in patients who develop “pre-eclampsia–
like” syndrome, including HTN and proteinuria, after
bevacizumab treatment showed features of throm-
botic microangiopathy (TMA), similar to what is seen
in severe pre-eclampsia (38). Given the infrequency
of renal biopsies, the true rate of TMA with VSP in-
hibitors is unknown. In a recent French study, renal
biopsies were done in 22 patients treated with various
VSP inhibitors, and TMA was observed in 21 biopsy
specimens (39), indicating that TMA might be
more common than originally thought. How VEGF
inhibition via sFlt-1 speciﬁcally leads to HTN in
pre-eclampsia is an area of active investigation.
Nevertheless, the similarities between pre-eclampsia
and VSP inhibitor–induced HTN and proteinuria sug-
gest similar underlying mechanisms.Card io-oncology cons iderat ions . There is no
simple algorithm to follow in managing HTN induced
by VSP inhibitors, and treatment needs to be indi-
vidualized for each patient. The Cardiovascular
Toxicities Panel of the National Cancer Institute
published an expert opinion on management of VSP
inhibitor–associated cardiac toxicity, including HTN,
on the basis of consensus rather than on clinical
outcome data (40). We proposed the following algo-
rithm (Figure 3) (modiﬁed from de Jesus-Gonzalez
et al. [12]).
ARTERIAL AND VENOUS THROMBOEMBOLISM. Incidence.
Patients with malignancies have increased risks of
thrombosis and hemorrhage. Numerous studies have
shown that the thromboembolic events are further
increased in cancer patients treated with VSP in-
hibitors. Table 4 summaries the incidences of arterial
TABLE 4 Incidences and Risks of Arterial and Venous Thromboembolism Associated With VSP Inhibitors
Agent Study (Ref. #)
Overall
Incidence of
VTE (%)
High-Grade VTE
(Grade 3–5)
(%)
RR of VTE
Study
Overall
Incidence of
ATE (%)
High-Grade ATE
(Grade 3–5)
(%)
RR of ATE
All-Grade High-Grade All-Grade High-Grade
Bevacizumab
(VEGF mAb)
Meta-analysis, 7,956
patients, 15 trials
(120)
11.9 6.3 1.33 1.38 Meta-analysis, 12,617
patients, 20 trials
(121)
3.3 2.0 1.44 2.14 (high-grade
cardiac ischemia)
Pazopanib
(TKI)
Meta-analysis, 7,441
patients, 17 trials
(sunitinib: 3 trials;
sorafenib: 4 trials;
pazopanib: 3 trials;
vandetanib:
5 trials; axitinib:
2 trials) (122)
2.76 1.92 1.10 0.85 Meta-analysis, 844
patients, 2 trials
(123)
1.2 NA 4.61 NA
Sunitinib
(TKI)
Meta-analysis, 4,628
patients, 4 trials
(124)
1.3 NA 3.1 NA
Sorafenib
(TKI)
Meta-analysis, 4,759
patients, 6 trials
(124)
1.7 NA 2.39 NA
Axitinib
(TKI)
Meta-analysis, 572
patients, 3 trials
(123)
1.2 NA 1.17 NA
Vandetanib
(TKIs)
Phase III RCT, 623
patients (123)
0 NA 0.13 NA
Regorafenib
(TKI)
Phase III RCT in
mCRC, 760
patients (125)
2 NA NA NA NA NA NA NA NA
Phase III RCT in
advanced GIST,
199 patients
(126)
No VTE or ATE events reported, but 1 patient
in regorafenib arm died from cardiac arrest
during treatment
Cabozantinib
(TKI)
Phase III RCT in MTC,
330 patients (112)
5.6 3.7 NA NA Phase III RCT in MTC
(112)
2.3 0.9 NA NA
Aﬂibercept
(VEGF trap)
Phase III RCT in
mCRC, 1,226
patients (127)
9.3 7.8 NA NA Phase III RCT in
mCRC, 1,226
patients (127)
2.6 1.8 NA NA
Ramucirumab
(VEGFR2 mAb)
Phase III RCT in
advanced gastric
or GEJ
adenocarcinoma,
665 patients
(128)
3.98 2.45 NA NA Phase III RCT in
advanced gastric
or GEJ
adenocarcinoma,
655 patients
(128)
1.83 0.92 NA NA
Lenvatinib
(TKI)
Phase III trial, 261
patients (116)
5.4 3.8 NA NA Phase III trial, 261
patients (116)
5.4 2.7 NA NA
ATE ¼ arterial thromboembolic event; GEJ ¼ gastroesophageal junction; mAb ¼ monoclonal antibody; mCRC ¼ metastatic colorectal cancer; MTC ¼ medullary thyroid cancer; RCT ¼ randomized controlled
trial; TKI ¼ tyrosine kinase inhibitor; VTE ¼ venous thromboembolic event; other abbreviations as in Table 3.
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1169and venous events in patients treated with these
agents.
VSP inhibitors are associated with increased risks
of both venous and arterial thromboembolic events;
paradoxically, they are also associated with hemor-
rhagic events. One meta-analysis of 14,277 patients
from 22 trials revealed that bevacizumab increases
risks of high-grade bleeding in a dose-dependent
manner (relative risk [RR]: 1.27 in low dose vs. 3.02
in high dose) (41). In a meta-analysis of 6,779 patients
from 23 trials, the RR of all-grade bleeding events
associated with sunitinib and sorafenib was 2.0 (95%
CI: 1.14 to 3.49; p ¼ 0.015) (42).
Mechan isms. ECs play a critical role in maintaining
vascular homeostasis. They maintain normal blood
vascular tone and viscosity, and prevent abnormal
blood clotting and bleeding. VEGF signaling maintainsEC integrity through activating survival and anti-
apoptotic signaling (43). VEGF also increases the
bioavailability of NO and prostacyclin, which, al-
though best known as vasodilators, also have several
vascular protective effects, including antiplatelet
activities. Therefore, VEGF inhibition can alter the
vascular hemostatic balance, interfere with the re-
generative capacity of ECs, and cause defects of the
endothelial layer that expose the underlying matrix,
leading to both thrombosis and hemorrhage (44). An
intriguing alternative hypothesis is that VSP inhibitors
can form immune complexes that activate platelets
and induce thrombosis (45,46).
Card io-oncology cons iderat ions . Due to the
presence of both thrombotic and hemorrhagic events,
it is a clinical dilemma as to whether antiplatelets or
anticoagulants should be used to prevent ATE or VTE
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1,745 patients treated with bevacizumab, baseline or
on-study aspirin use was associated with modest in-
creases in grade 3 and 4 bleeding events, from 3.6% to
4.7% for bevacizumab-treated patients and from 1.7%
to 2.2% for control subjects. The net clinical beneﬁts
of aspirin could not be assessed due to the small
number of patients taking aspirin (47). Aspirin-based
prophylaxis should be carefully considered for indi-
vidual patients who are at high risk for ATEs. In a
retrospective analysis of patients with metastatic
colorectal cancer or advanced non–small cell lung
cancer treated with bevacizumab and full-dose anti-
coagulation for VTE, bleeding complications were not
signiﬁcantly increased, suggesting that it may be safe
to administer full-dose anticoagulation during bev-
acizumab treatment (48). Large, prospective clinical
trials are needed to conﬁrm whether anticoagulants
can be given safely to patients on VSP inhibitors.
VSP INHIBITOR–RELATED HYPOGLYCEMIA. Emerg-
ing data suggest that some VSP inhibitors may affect
glucose homeostasis. Sunitinib and sorafenib
decrease blood glucose levels (49) and have been re-
ported to induce cases of severe hypoglycemia
(50,51). Further validation of sunitinib’s glucose-
lowing effect comes from studies showing that suni-
tinib therapy reduces the need for hyperglycemia
treatment in patients with diabetes (52). The
underlying mechanisms for VSP inhibitor–associated
hypoglycemia remain unclear, but it may be an off-
target effect, due to inhibition of PDGF signaling
(53). Clinically, a diabetic regimen needs to be care-
fully reviewed and potentially modiﬁed in diabetic
patients treated with these agents, and glucose levels
should be closely monitored during treatment.
BCR-ABL INHIBITORS
Small-molecule TKIs have been most successful in
treatment of CML. Imatinib was initially developed as
a platelet-derived growth factor receptor (PDGFR)
inhibitor, but was also found to inhibit other kinases,
such as ABL and c-KIT (the stem cell factor receptor).
In 2001, imatinib became the ﬁrst small-molecule TKI
approved by the FDA and has revolutionized the
treatment of CML and other leukemias where the ABL
TK is constitutively active.
Although imatinib has dramatically altered the
natural history of CML,more than 30% of patients with
CML will either be unable to tolerate or will develop
resistance to imatinib. As a result, newer generations
of BCR-ABL kinase inhibitors—dasatinib, nilotinib,
bosutinib, and ponatinib—have been developed. Nilo-
tinib is a close analog of imatinib with increasedselectivity and approximately 20-fold higher potency
against BCR-ABL (54). Dasatinib is a dual-speciﬁcity
ABL- and SRC-family kinase inhibitor and is 100-fold
more active against BCR-ABL in cell-based assays
(55). Only ponatinib inhibits the “gatekeeper” T315I
mutation, which is present in up to 20% of patients
with resistance to other tyrosine kinase inhibitors (56).
Because the newer TKIs are more potent than
imatinib, they are increasingly being used as front-
line therapy for CML; nilotinib and dasatinib have
FDA approval speciﬁcally for that indication. Whereas
early data suggest that patients treated with newer
agents achieve more rapid and deeper molecular
response and have decreased progression to acceler-
ated phase and blast crisis, this has not translated
into better overall survival (57,58).
UNIQUE AND DIVERSE VASCULAR SAFETY PROFILES
ASSOCIATED WITH BCR-ABL INHIBITORS. Vascular
safety is an emerging challenge in patients treated
with BCR-ABL inhibitors, especially the newer-
generation agents. The various TKIs have distinct
vascular safety proﬁles, most likely due to each
compound’s different kinase inhibition proﬁles and
non-kinase targets.
Vascula r safety of imat in ib . Vascular toxicity is
rare with imatinib treatment; in fact, on the basis of
pre-clinical data and clinical observations, imatinib
may actually have beneﬁcial roles in the vasculature.
Imatinib attenuates in-stent restenosis (59) and
diabetes-associated atherosclerosis in a mouse model
(60). Early clinical data suggests that imatinib lowers
glucose levels in both diabetic and nondiabetic pa-
tients (49). Interestingly, in a large retrospective
cohort analysis, patients with CML on imatinib
treatment had lower rates of peripheral events
compared with those treated initially with placebo
(61). Such favorable effects also extend to the pul-
monary vasculature, where pre-clinical data sug-
gesting reversal of pulmonary arterial hypertension
(PAH) has led to several clinical trials testing imati-
nib’s potential role in the treatment of PAH (62).
Dasatinib-associated PAH and possible mechanisms.
Despite the favorable vascular safety proﬁle of im-
atinib, PAH can result from dasatinib. Recently,
a French PAH registry reported a series of 9 dasatinib-
associated PAH cases. All patients were diagnosed
during treatment; the median time between initia-
tion of dasatinib therapy and PAH diagnosis was
34 months (range 8 to 48 months) (63). At diagnosis,
most patients had severe clinical, functional, and
hemodynamic impairment with minimal acute vaso-
dilator response, suggesting that isolated acute vaso-
constriction may not represent the main mechanism
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failed to demonstrate complete hemodynamic recov-
ery, and 2 died due to sudden death or cardiac failure
at follow-up. Importantly, no PAH was reported in
the context of other TKIs used for CML therapy in
this registry.
It is difﬁcult to estimate the incidence of dasatinib-
associated PAH, because pulmonary pressures have
not been systematically assessed in trials of dasatinib.
The authors of the French registry estimated the
lowest incidence of PAH in patients exposed to
dasatinib to be 0.45%. In a Korean single-center
study, 89 CML patients treated with dasatinib were
followed for 6 years, and echocardiography was used
to assess PAH. Patients with abnormal right ventric-
ular systolic pressure or symptoms suggestive of PAH
were evaluated with additional studies (such as
catheterization) for a more deﬁnitive diagnosis. In the
Korean series, 12.1% of patients developed PAH (64).
The mechanism of dasatinib-associated PAH remains
unclear.
Interestingly, dasatinib is associated with a higher
incidence of pleural effusion, reported to range from
14% to 35% (65). The mechanisms underlying devel-
opment of pleural effusion during dasatinib therapy
are unclear, but are probably immune-mediated (66).
When patients develop symptoms (i.e., chest pain,
dyspnea, and dry cough) that can also occur in PAH,
careful clinical examination and diagnostic tests are
crucial in differential diagnosis.
Ni lot in ib-assoc ia ted vascula r tox ic i t ies and
poss ib le mechan isms . More recently, vascular tox-
icities have emerged as a critical concern with nilo-
tinib (67–70). In a retrospective analysis of 179
patients who received nilotinib in 4 centers, 11
(6.15%) patients developed severe and previously
unrecognized peripheral atherosclerosis that required
invasive therapy, including angioplasty and limb
amputation (67). In a 3-year follow-up of a pivotal
trial comparing imatinib and nilotinib in newly diag-
nosed CML patients, 7 patients on nilotinib developed
vascular events (VE), equating to a frequency of 1.2%
after a median follow-up of 3 years, whereas there
were no VE in the imatinib arm (71). After a follow-up
of 4 years, 2 additional VE have occurred in the
nilotinib arm (72).
Unfortunately, in most clinical trials with nilotinib,
VE was not systematically evaluated or graded
(58,73,74). A prospective study of 129 patients with
CML systematically assessed ankle-brachial index in
all patients. Peripheral arterial disease was discov-
ered in 6.3% with ﬁrst-line imatinib, 26% with ﬁrst-
line nilotinib, and 35.7% with second-line nilotinib—
far higher than previously reported (72), suggestingthe possibility that accelerated atherosclerosis may
be the underlying cause of nilotinib-associated
vascular events. Indeed, several clinical studies sug-
gest that nilotinib is associated with elevations in
glucose (71), total cholesterol, and LDL (72), which are
risk factors for developing atherosclerosis. A more in-
depth study of glucose metabolism in 10 CML patients
receiving nilotinib demonstrated insulin resistance
and compensatory hyperinsulinemia (75). Nilotinib
treatment is also associated with hypothyroidism,
which can affect lipid and glucose metabolism (76).
Therefore, an accelerated metabolic dysregulation
may be involved in the formation of atherosclerotic
plaques and pathogenesis of vascular atherosclerosis.
Ponat in ib-assoc iated vascular tox ic i t ies and
poss ib le mechan isms . Ponatinib was initially
approved via the FDA’s expedited program for drug
approval after encouraging results from a phase 2
study of 449 patients who had failed other TKIs (56).
With a median follow-up of 12.8 months, the reported
CV, cerebrovascular, and peripheral VEs were 2.2%,
0.7%, and 1.6%, respectively (77). These numbers
were deemed as not concerning given ponatinib’s
anticancer potency. Subsequent follow-up conﬁrmed
ponatinib as highly effective in CML patients who had
become resistant to other TKIs; for these patients, the
only other treatment option would be a stem cell
transplant, which would portend signiﬁcant
morbidity. However, over a median follow-up of 27.9
months, serious “arterial thrombotic events”
occurred in 19% of ponatinib-treated patients,
including CV events (10%), cerebrovascular events
(7%), and peripheral VEs (7%), with some patients
having more than 1 event. In addition, 5% patients
experienced VTE (78). At least 5 patients died from
VEs thought to be due to ponatinib. Because of the
severe vascular complications detected during an
interval analysis of the trial at 24 months, sale of
ponatinib in the United States was temporarily sus-
pended in October 2013. However, after further
assessment of the data and consideration of the lack
of other effective treatments available for T315I
mutant CML, sale of ponatinib resumed in January
2014 under narrower indications for treatment and a
black box warning about increased risk of arterial and
venous occlusive events (79). Retrospective analysis
of the phase III trial suggests older age ($65 years,
RR: 1.8), history of ischemic disease (RR: 2.6), dia-
betes (RR: 2.5), and HTN (RR: 3.2) as risk factors
associated with serious arterial thrombotic events
during ponatinib treatment (78).
The underlying mechanisms of ponatinib-induced
VE are largely unknown. In a recent study, ponati-
nib blocked platelet immune-receptor tyrosine-based
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1172activation motif signaling, as well as platelet
spreading, aggregation, and aggregate formation.
Thus, ponatinib serves as a platelet antagonist, sug-
gesting that the VEs are not due to platelet activation
(80). Vascular toxicities may also represent off-target
side effects. Ponatinib inhibits numerous other TKs,
including SRC, FGFR, PDGFR, and VEGFR1–3, which
are important kinases in the vasculature (81). The
potency of ponatinib inhibition against VEGFR-2 is
similar to the VSP inhibitors sunitinib and sorafenib
(82), thus explaining the high incidence of HTN
(26%) in patients treated with ponatinib (78). It re-
mains to be seen how much of the vascular events
associated with ponatinib are due to these off-target
kinase inhibitions, speciﬁcally VEGFR-2. The use of
lower doses of ponatinib (i.e., a starting dose of 15
or 30 mg, rather than the FDA-approved dose of
45 mg) is also being explored in a randomized trial,
in which vascular safety will be carefully assessed
(NCT02398825).
CARDIO-ONCOLOGY CONSIDERATIONS. BCL-ABL
kinase inhibitors have transformed the prognosis of
CML, and as a result, many patients taking TKIs for
CML will be on therapy for 10 years or longer. The 4-
year overall survival rate for CML patients is as high
as 95% (83), and survival rates of CML patients who
experience a complete cytogenetic response is com-
parable to their age-matched control subjects (84).
Therefore, it is essential for physicians to prevent
and manage acute and chronic CV complications
associated with these agents.
Patients taking TKIs for CML, especially agents
other than imatinib, need to be carefully counseled
about management of modiﬁable risk factors for car-
diac and vascular events (Figure 4). In addition, some
investigators have proposed speciﬁc screening tools
when considering TKI therapy. For instance, it has
been proposed that patients starting dasatinib should
be routinely screened for PAH by echocardiography,
although this is not yet a standard practice (63). A
validated score system, such as the European Society
of Cardiology score, could be used to determine the
individual risk of vascular events before prescribing
nilotinib or ponatinib. Given the high frequency of
VEs associated with nilotinib, it should probably not
be prescribed as front line therapy for patients with
multiple risk factors for vascular disease (e.g., smok-
ing, HTN, diabetes, hypercholesterolemia) if other
agents are available (85). Because ponatinib-induced
vascular toxicity can be severe, and sometimes fatal,
until further data are available, ponatinib should only
be considered in patients who either have the T315I
mutation or have not tolerated or not responded to
other TKIs, and CV risk factors need to be tightlycontrolled and optimized when the drug is started.
It is unclear whether antiplatelet agents or anticoag-
ulants should be routinely used in conjunction with
ponatinib, and although some clinicians have initi-
ated this practice, the risk of bleeding from cytope-
nias or thrombocytosis needs to be considered. We do
suggest a low threshold for involvement of cardio-
logists in the care of CML patients being treated
with second-line therapies, especially nilotinib or
ponatinib.
PI3K/AKT/mTOR INHIBITORS
PI3Ks are lipid kinases that are major downstream
effectors of RTKs and G-protein–coupled receptors
(GPCRs) and regulate diverse cellular processes by
activating downstream mediators, such as the serine/
threonine kinases AKT and mTOR (Figure 5). The
PI3K/AKT/mTOR signaling cascade is 1 of the most
important intracellular pathways and is frequently
mutated in cancers (86). PI3Ks can be divided into
3 classes (I, II, III) on the basis of their structural
characteristics and substrate and tissue speciﬁcity.
Class I PI3Ks are the best characterized and are sub-
divided into Class IA and IB. Class IA PI3K (consisting
of a p85 regulatory subunit and a p110 catalytic sub-
unit: p110a, p110b, or p110d) is activated by both RTKs
and GPCRs, whereas class IB PI3K (consisting of a p101
regulatory subunit and a p110g catalytic subunit) is
activated by GPCRs (87).
Drugs targeting the PI3K/AKT/mTOR pathway have
emerged as important cancer therapies. Currently, 1
p110d-speciﬁc inhibitor (idelalisib) and 2 mTORC1 in-
hibitors (everolimus and temsirolimus) have been
granted FDA approval. Additionally, a multitude of
pan-PI3K inhibitors, p110a-speciﬁc inhibitors, dual
PI3K/mTOR inhibitors, AKT inhibitors, and dual
mTORC1/mTORC2 inhibitors are in clinical trials
(Figure 5), either as single agents or in combination
with other agents.
CARDIAC AND METABOLIC CONSIDERATIONS DURING
THE ONGOING CLINICAL TRIALS TARGETING PI3K/
AKT/MTOR. PI3K/AKT/mTOR also plays critical roles
in the CV system. Insulin and insulin growth factor
are potent activators of PI3K/AKT/mTOR signaling
in cardiac myocytes and have been implicated in
cardiac hypertrophy and protection of myocytes
from apoptosis (88). Among the class I PI3Ks
expressed in the heart, p110a and p110g are more
highly expressed than p110b and p110d (89). The roles
of different PI3K isoforms in the CV system have not
been extensively evaluated, but evidence from
transgenic and knockout mice studies indicates that
different isoforms may have distinct effects. In a
FIGURE 4 Proposed CV Risk Assessment and Management in CML Patients Receiving TKI Treatment
Low CV risk patients
High CV risk patients-
Known CAD/PAD
-Diabetes
-Two or more
cardiovascular risk
factors (age>60, HTN,
dyslipidemia, active
tobacco use)
High CV risk TKI Therapy
(Nilotinib or Ponatinib)
Low CV risk TKI Therapy
(Imatinib or Dasatinib)
High CV risk TKI Therapy
(Nilotinib or Ponatinib)
•Standard CV primary prevention and
drug-specific side effect monitoring
•Standard CV primary or secondary prevention
and drug-specific side effect monitoring
•Standard CV primary prevention and
drug-specific side effect monitoring
Low CV risk TKI Therapy
(Imatinib or Dasatinib)
Intensified CV risk assessment and
management
Pre-treatment:
Surveillance (every 3-6 months):
-Screen for symptomatic CAD, PAD, or CHF.
-Aggressive medical management of CV risk
factors (HTN, dyslipidemia, diabetes etc)
-Ongoing screening for development of CAD,
PAD, or CHF symptoms.
-Continued monitoring and aggressive control
of CV risk factors
-Timely referral to cardiologist if CV
symptoms occur
-Consider dose reduction or switching to
alternative TKI in patients with uncontrolled
severe HTN or new CV events
CAD ¼ coronary artery disease; CHF ¼ congestive heart failure; CML ¼ chronic myelogenous leukemia; CV ¼ cardiovascular; HTN ¼ hypertension; PAD ¼ peripheral
arterial disease; TKI ¼ tyrosine kinase inhibitor.
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1173cardiac-speciﬁc transgenic mouse model expressing a
constitutively active PI3K (p110a) mutant, heart size
was signiﬁcantly increased due to cardiac hypertro-
phy, but the cardiac function and lifespan were
normal. In contrast, in a cardiac-speciﬁc mouse model
expressing a dominant negative PI3K (p110a) mutant,
the heart was signiﬁcantly smaller. Under basal con-
ditions, cardiac function in these mice was not
compromised. However, in the presence of pathologic
stimuli, cardiac function and lifespan were signiﬁ-
cantly decreased (90), indicating the importance of
p110a in maintaining cardiac structure and function
in pathological settings of stress. This raises concern
that the p110a-speciﬁc and pan-PI3K inhibitors may
cause cardiac dysfunction. However, PI3K (p110g),
which is linked to GPCRs, is critical for the induction
of myocardial hypertrophy, interstitial ﬁbrosis, and
cardiac dysfunction in response to b-adrenergic
receptor stimulation in vivo. PI3K (p110g) knockoutmice are actually protected against isoproterenol-
induced heart failure, suggesting that PI3K (p110g)
mediates pathological cardiac hypertrophy (91). AKT
and mTOR are also involved in cardiac hypertrophy
and survival. Recent evidence suggests that activa-
tion of this pathway is likely to counteract ﬁbrosis
and cell death, thus preserving cardiac function (88).
This suggests that inhibiting AKT or mTOR might
result in deterioration of cardiac function in patients
with baseline cardiac hypertrophy (92). Thus, given
the complexity of the PI3K/AKT/mTOR pathway in
the CV system, close monitoring of cardiac function is
warranted during ongoing clinical trials of these
novel agents.
The PI3K/AKT/mTOR pathway can modulate the
insulin-signaling pathway (93). PI3K knockout mice
display hyperinsulinemia, insulin resistance, and
glucose intolerance (94). In a mouse model of
type 2 diabetes, mTOR inhibition increased insulin
FIGURE 5 PI3K/AKT/mTOR Signaling Pathway and Inhibition Strategies
Many novel agents targeting this signaling pathway are under clinical development. mTORC ¼ mammalian target of rapamycin complex;
RTK ¼ receptor tyrosine kinase; other abbreviations as in Figures 1 and 2.
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(95). In rat adipose cells, PI3K and mTOR inhibitors
impaired the insulin-signaling pathway regulating
lipoprotein lipase (LPL) (96).
METABOLIC TOXICITIES ASSOCIATED WITH PI3K/
AKT/MTOR INHIBITORS. Due to the important role
of PI3K/AKT/mTOR signaling in glucose and lipid
metabolism, targeting this pathway for cancer treat-
ment would be predicted to cause a spectrum of
metabolic derangements, including hypercholester-
olemia, hypertriglyceridemia, and hyperglycemia.
For this reason, patients with diabetes and ischemic
heart disease were often excluded from clinical
trials (97); data on the speciﬁc incidence and spec-
trum of metabolic toxicities during treatment with
PI3K/AKT/mTOR pathway inhibitors are therefore
incomplete. Still, a high incidence of unfavorable
metabolic adverse effects was observed to be as-
sociated with these agents. In a phase III trial
evaluating everolimus in metastatic renal cell carci-
noma (mRCC), the incidences of hypertriglyceridemia,hypercholesterolemia, and hyperglycemia were 71%,
76%, and 50%, respectively, which were signiﬁcantly
higher than placebo (30%, 32%, and 23%, respectively)
(97). Similar ﬁndings were reported in a clinical trial
using temsirolimus in advanced renal cell carcinoma
(98). The most common laboratory abnormalities
associated with idelalisib are hyperglycemia and
hypertriglyceridemia, which occurred in 54% and 56%
of patients, respectively (99). The frequency of
elevation in LDL, an important atherogenic compo-
nent of cholesterol, is not known because it is not 1 of
the adverse events listed in the CTCAE and is not often
reported in oncology trials (100).
CARDIO-ONCOLOGY CONSIDERATIONS. Owing to
the signiﬁcant effect of mTOR inhibitors on lipid and
glucose metabolism, the Task Force of National
Cancer Institute Investigational Drug Steering Com-
mittee has proposed speciﬁc management of the
metabolic side effects of these agents (Table 5) (100).
Because idelalisib was just approved by the FDA in
2014, clinical experience regarding the incidence of
TABLE 5 Summary of Glycemic and Lipid Thresholds for Eligibility, Goals, Dose-Limiting Toxicity, and Management
Glucose Lipid
Eligibility for trials Fasting glucose <160 mg/dl LDL <190 mg/dl
Triglycerides <300 mg/dl
Goals on trials HbA1C #8%
Fasting glucose <160 mg/dl
Random glucose <200 mg/dl
LDL <190 mg/dl if no CV risk factors; LDL <100 mg/dl if high risk;
Triglycerides <300 mg/dl
Dose-limiting toxicity Grade 3 or asymptomatic grade 4 hyperglycemia
not improving despite appropriate treatment
for 1 week
Symptomatic grade 4 hyperglycemia (>500 mg/dl)
Grade 3 to 4 hyperlipidemia (total cholesterol >400 mg/dl or
triglycerides >500 mg/dl) not improving despite appropriate
treatment for 4 weeks
Management Grade 2 hyperglycemia (161–250 mg/dl): lifestyle modiﬁcation,
metformin; if not controlled, add sulfonylurea; if still not
controlled, add basal insulin
Asymptomatic grade 3 hyperglycemia (250–500 mg/dl): begin
metformin and sulfonylurea; if not controlled, add basal insulin;
if not controlled, stop oral agents, add pre-meal insulin
Symptomatic stage 3 hyperglycemia (250–500 mg/dl) or
grade 4 hyperglycemia (>500 mg/dl): baseline insulin,
pre-meal insulin, and diabetes consultation
Triglycerides 150–299 mg/dl: lifestyle modiﬁcation, treat LDL to target
Triglycerides 300–499 mg/dl: lifestyle modiﬁcation, treat LDL
to target, consider drug therapy, especially if high CV risk
Triglyceride $500 mg/dl: lifestyle modiﬁcation þ drug therapy
(ﬁbrate, omega-3 acid, extended-release niacin)
Elevated LDL should be treated with statins if lifestyle
modiﬁcation fails
Modiﬁed from Busaidy et al. (100).
CV ¼ cardiovascular; HbA1C ¼ glycated hemoglobin; LDL ¼ low-density lipoprotein.
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agement is lacking.
SUMMARY AND FUTURE DIRECTIONS
Kinase inhibitors are important anticancer agents and
have improved oncological outcomes. Novel agents in
development hold considerable promise. However,
CV and metabolic adverse events need to be consid-
ered and carefully managed when treating patients
with these agents. Further insights into the mecha-
nism underlying these adverse events may allow
design of more narrowly targeted agents with fewer
off-target effects. In the meantime, CV specialists andoncologists need to work closely to better deﬁne
cardiac, vascular, and metabolic perturbations that
can affect cancer patients during anticancer treat-
ment and survivorship.
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